NCT05257265View on ClinicalTrials.gov

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

459

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

September 29, 2023

Study Completion Date

October 5, 2023

Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
DRUG

Centanafadine Hydrochloride

Capsule

OTHER

Placebo

Capsule

Trial Locations (1)

10012

For additional information regarding sites, contact 844-687-8522, New York

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY